A Phase 1 Study of PRT3789, a Potent and Selective Degrader of SMARCA2 in Patients with Advanced or Metastatic Solid Tumors and a SMARCA4 Mutation

Ibiayi Dagogo‐Jack, Afshin Dowlati, Robin Guo, Mark Awad, Aurelie Swalduz, Emiliano Calvo, Victor Moreno, Alex Adjei, Patricia LoRusso, Salman Punekar, Ticiana Leal, Timothy A. Yap, Antoine Italiano, William Novotny, Chris Tankersley, Sarah Rowe, Gina Paris, William Sun, Alex Spira, and Benjamin Besse